key: cord-0053022-ira8w8km
authors: Kumar, Amit; Saxena, Ajit Kumar; Lee, Gwo Giun (Chris); Kashyap, Amita; Jyothsna, G.
title: Rational Drug Design and Docking of the RNA Dependent RNA Polymerase Domain of NCoV
date: 2020-09-27
journal: Novel Coronavirus 2019
DOI: 10.1007/978-981-15-7918-9_5
sha: 86cfc06047aeae8e81804c6af4f79177e2ffcb45
doc_id: 53022
cord_uid: ira8w8km

It is an urgent requirement of 2020 to develop a drug which can successfully treat the patients of COVID19 and gift them a healthy life back.

One of the important points to be considered in the treatment or the drug development for COVID 19 is time constraint. Currently Drug repurposing [1] is the best option that can be considered for the development of drugs in the treatment of the COVID victims.

In view of the above comparative analysis between MERS CoV and Novel Corona Virus 2019 which revealed a close genetic relation, all the medications that were successful in treating MERS can be used in the therapy of COVID with the molecular mechanism studied. All the drugs and their structures are obtained from two important public databases which are PUBCHEM [2] and CHEBI [3] .

A Selection of Chemicals 1. Remdesivir:

This is an active inhibitor for the RNA dependent RNA polymerase enzyme which was already tested and proved to be effective against MERS [4] (https://www.jbc. org/content/early/2020/02/24/jbc.AC120.013056).

One of the study by Elfiky et al. [5] on MERS therapy stated that Guanosine derivatives are good inhibitors for virus polymerases (https://www.tandfonline.com/ doi/full/10.1080/07391102.2020.1758789) and can be used in treating MERS which was validated by in silico docking studies. Thus these derivatives along with the proposed other drugs can be tested for COVID therapy. The compounds tested in the study were as follows:

2. Guanosine triphosphate (GTP) 3. Uridine triphosphate (UTP), 4. IDX-184 (GTP derivative), 5. Sofosbuvir (UTP derivative) 6. Ribavirin (wide acting antiviral drug)

The data has been retrieved from two data bases CHEBI and PUBCHEM 

The docking association of the above six ligands with RNA-dependent RNA polymerase domain was studied on HEX [12] and illustrated as follows: The docking was performed between the selected ligands and the PDB structure 7btf corresponding to the RNA dependent RNA polymerase domain of ORF1AB protein. All the docking energies are energetically favorable and closer except Ribavirin. This indicates that the ligands Remdesivir, IDX-184 and Guanosine triphosphate etc can be used as efficient drugs. 

Drug repositioning is an alternative for the treatment of coronavirus COVID-19

PubChem 2019 update: improved access to chemical data

The ChEBI reference database and ontology for biologically relevant chemistry: enhancements for 2013

The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus

Novel guanosine derivatives against MERS CoV polymerase: an in silico perspective

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Stathmin slows down guanosine diphosphate dissociation from tubulin in a phosphorylation-controlled fashion

Stability and structure of mixed-ligand metal ion complexes that contain Ni 2+ , Cu 2+ , or Zn 2+ , and Histamine, as well as adenosine 5'-triphosphate (ATP4-) or uridine 5'-triphosphate (UTP(4-): an intricate network of equilibria

Knowledge-based protein secondary structure